Skip to main content

Table 4 Effect of age and gender on mean difference in FSIQ

From: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

  Difference in mean FSIQ
(95% CI)
p-value Difference in mean FSIQ
(95% CI)
p-value
  Age < 5 Age > 5   Male Female  
Controls vs. patients
3 years 7.7
(3.7: 11.7)
5.0
(1.2: 8.8)
ns 8.3
(4.5: 12.1)
5.6
(1.7: 9.5)
ns
5 years 5.6
(1.3: 9.9)
3.6
(-1.5: 8.7)
ns 5.5
(1.1: 9.9)
4.6
(-0.4: 9.6)
ns
HDM vs. IT MTX
3 years -0.1
(-4.9: 4.6)
1.0
(-5.7: 7.7)
ns -0.9
(-6.4: 4.5)
0.0
(-5.7: 5.8)
ns
5 years 1.6
(-3.5: 6.7)
-6.6
(-14.5: 1.3)
ns -1.3
(-7.6: 5.0)
-1.7
(-8.0: 4.6)
ns
HDM vs. XRT
3 years 4.2
(-3.4: 11.9)
4.2
(-3.5: 11.8)
ns 3.6
(-3.8: 11.0)
4.8
(-3.1: 12.6)
ns
5 years 5.5
(-5.9: 13.4)
-0.4
(-10.8: 10.0)
ns 2.1
(-7.0: 11.2)
1.5
(-12.2: 15.2)
ns